These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22859825)

  • 1. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children.
    Weinberg A; Song LY; Saah A; Brown M; Moscicki AB; Meyer WA; Bryan J; Levin MJ;
    J Infect Dis; 2012 Oct; 206(8):1309-18. PubMed ID: 22859825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine.
    Levin MJ; Huang S; Moscicki AB; Song LY; Read JS; Meyer WA; Saah AJ; Richardson K; Weinberg A;
    Vaccine; 2017 Mar; 35(13):1712-1720. PubMed ID: 28238631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.
    Gilca V; Sauvageau C; Boulianne N; De Serres G; Crajden M; Ouakki M; Trevisan A; Dionne M
    Hum Vaccin Immunother; 2015; 11(3):732-8. PubMed ID: 25714044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.
    Gilca V; Sauvageau C; Boulianne N; De Serres G; Couillard M; Krajden M; Ouakki M; Murphy D; Trevisan A; Dionne M
    Hum Vaccin Immunother; 2014; 10(8):2438-45. PubMed ID: 25424952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.
    Levin MJ; Moscicki AB; Song LY; Fenton T; Meyer WA; Read JS; Handelsman EL; Nowak B; Sattler CA; Saah A; Radley DR; Esser MT; Weinberg A;
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):197-204. PubMed ID: 20574412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children.
    Weinberg A; Huang S; Moscicki AB; Saah A; Levin MJ;
    AIDS; 2018 Apr; 32(7):851-860. PubMed ID: 29424778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
    Luxembourg A; Brown D; Bouchard C; Giuliano AR; Iversen OE; Joura EA; Penny ME; Restrepo JA; Romaguera J; Maansson R; Moeller E; Ritter M; Chen J
    Hum Vaccin Immunother; 2015; 11(6):1313-22. PubMed ID: 25912208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort.
    Kann H; Lehtinen M; Eriksson T; Surcel HM; Dillner J; Faust H
    J Infect Dis; 2021 Jun; 223(11):1992-2000. PubMed ID: 33009576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
    Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R
    Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
    Mugo N; Ansah NA; Marino D; Saah A; Garner EI
    Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM).
    Hidalgo-Tenorio C; Ramírez-Taboada J; Gil-Anguita C; Esquivias J; Omar-Mohamed-Balgahata M; SamPedro A; Lopez-Ruz M; Pasquau J
    AIDS Res Ther; 2017 Jul; 14(1):34. PubMed ID: 28720147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus.
    McClymont E; Lee M; Raboud J; Coutlée F; Walmsley S; Lipsky N; Loutfy M; Trottier S; Smaill F; Klein MB; Harris M; Cohen J; Yudin MH; Wobeser W; Money D;
    Clin Infect Dis; 2019 Feb; 68(5):788-794. PubMed ID: 29985988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study.
    Grein IHR; Pinto NBF; Groot N; Martins CB; Lobo A; Aikawa NE; Barbosa C; Terreri MT; da Fraga ACM; de Oliveira SKF; Sztajnbok F; Paim Marques LB; Islabão AG; Appenzeller S; Bica B; de Oliveira Sato J; Magalhães CS; Ferriani V; Pasmans H; Schepp R; van der Klis F; de Roock S; Wulffraat N; Pileggi GS
    Pediatr Rheumatol Online J; 2020 Nov; 18(1):87. PubMed ID: 33176806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection.
    Zurek Munk-Madsen M; Toft L; Kube T; Richter R; Ostergaard L; Søgaard OS; Tolstrup M; Kaufmann AM
    Hum Vaccin Immunother; 2018 Apr; 14(4):909-916. PubMed ID: 29172992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
    Faust H; Toft L; Sehr P; Müller M; Bonde J; Forslund O; Østergaard L; Tolstrup M; Dillner J
    Vaccine; 2016 Mar; 34(13):1559-1565. PubMed ID: 26896686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
    Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
    Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine.
    Money DM; Moses E; Blitz S; Vandriel SM; Lipsky N; Walmsley SL; Loutfy M; Trottier S; Smaill F; Yudin MH; Klein M; Harris M; Cohen J; Wobeser W; Bitnun A; Lapointe N; Samson L; Brophy J; Karatzios C; Ogilvie G; Coutlée F; Raboud J;
    Vaccine; 2016 Sep; 34(40):4799-806. PubMed ID: 27544584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal ≥ HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years.
    Hidalgo-Tenorio C; Pasquau J; Omar-Mohamed M; Sampedro A; López-Ruz MA; López Hidalgo J; Ramírez-Taboada J
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33498165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.